Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes
Mercedes Iñarrairaegui, Ignacio Melero, Bruno Sangro
Clinical Cancer Research (2017) Vol. 24, Iss. 7, pp. 1518-1524
Open Access | Times Cited: 216

Showing 1-25 of 216 citing articles:

Molecular therapies and precision medicine for hepatocellular carcinoma
Josep M. Llovet, Robert Montal, Daniela Sia, et al.
Nature Reviews Clinical Oncology (2018) Vol. 15, Iss. 10, pp. 599-616
Open Access | Times Cited: 1624
Challenges in liver cancer and possible treatment approaches
David Anwanwan, Santosh Kumar Singh, Shriti Singh, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2019) Vol. 1873, Iss. 1, pp. 188314-188314
Open Access | Times Cited: 1160
Molecular and histological correlations in liver cancer
Julien Caldéraro, Marianne Ziol, Valérie Paradis, et al.
Journal of Hepatology (2019) Vol. 71, Iss. 3, pp. 616-630
Open Access | Times Cited: 433
Inflammation and Liver Cancer: Molecular Mechanisms and Therapeutic Targets
Yoon Mee Yang, Sohee Kim, Ekihiro Seki
Seminars in Liver Disease (2019) Vol. 39, Iss. 01, pp. 026-042
Open Access | Times Cited: 341
Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review
Kyoko Oura, Asahiro Morishita, Joji Tani, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 11, pp. 5801-5801
Open Access | Times Cited: 313
Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1‐6 hepatocellular carcinoma model
Takayuki Kimura, Yu Kato, Yoichi Ozawa, et al.
Cancer Science (2018) Vol. 109, Iss. 12, pp. 3993-4002
Open Access | Times Cited: 278
Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities
Stephen P. Hack, Andrew X. Zhu, Yulei Wang
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 201
Sorafenib Induces Pyroptosis in Macrophages and Triggers Natural Killer Cell–Mediated Cytotoxicity Against Hepatocellular Carcinoma
Carina Hage, Sabine Hoves, Léanne Strauss, et al.
Hepatology (2019) Vol. 70, Iss. 4, pp. 1280-1297
Closed Access | Times Cited: 181
Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response
Bridget P. Keenan, Lawrence Fong, Robin Kate Kelley
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 175
Designer exosomes for targeted and efficient ferroptosis induction in cancer via chemo-photodynamic therapy
Jianbing Du, Zhuo Wan, Cong Wang, et al.
Theranostics (2021) Vol. 11, Iss. 17, pp. 8185-8196
Open Access | Times Cited: 171
The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications
Jiajie Hou, Haiyan Zhang, Beicheng Sun, et al.
Journal of Hepatology (2019) Vol. 72, Iss. 1, pp. 167-182
Open Access | Times Cited: 154
Immune Checkpoint Inhibitors in the Treatment of HCC
Clelia Donisi, Marco Puzzoni, Pina Ziranu, et al.
Frontiers in Oncology (2021) Vol. 10
Open Access | Times Cited: 108
Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study
Jianming Shen, Hui Shen, Lixin Ke, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 107
YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD‐L1/VEGFA Axis
Jingyuan Wen, Xue Lin, Wei Yi, et al.
Advanced Science (2024) Vol. 11, Iss. 13
Open Access | Times Cited: 26
Review article: systemic treatment of hepatocellular carcinoma
Matthias Pinter, Markus Peck‐Radosavljevic
Alimentary Pharmacology & Therapeutics (2018) Vol. 48, Iss. 6, pp. 598-609
Open Access | Times Cited: 150
EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma
Gang Xiao, Li-Lian Jin, Chaoqun Liu, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 144
Hepatocellular Carcinoma with Portal Vein Tumor Involvement: Best Management Strategies
Po‐Hong Liu, Teh–Ia Huo, Rebecca A. Miksad
Seminars in Liver Disease (2018) Vol. 38, Iss. 03, pp. 242-251
Closed Access | Times Cited: 127
Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma
Bettina Langhans, Hans Dieter Nischalke, Benjamin Krämer, et al.
Cancer Immunology Immunotherapy (2019) Vol. 68, Iss. 12, pp. 2055-2066
Open Access | Times Cited: 125
An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinoma
Yifei Dai, Weijie Qiang, Kequan Lin, et al.
Cancer Immunology Immunotherapy (2020) Vol. 70, Iss. 4, pp. 967-979
Open Access | Times Cited: 124
Restoring, releasing or replacing adaptive immunity in chronic hepatitis B
Mala K. Maini, Alice R. Burton
Nature Reviews Gastroenterology & Hepatology (2019) Vol. 16, Iss. 11, pp. 662-675
Open Access | Times Cited: 111
EpCAM-high liver cancer stem cells resist natural killer cell–mediated cytotoxicity by upregulating CEACAM1
Dong Jun Park, Pil Soo Sung, Jung‐Hee Kim, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 1, pp. e000301-e000301
Open Access | Times Cited: 95
Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment
Amblessed Onuma, Hongji Zhang, Hai Huang, et al.
Gene Expression (2020) Vol. 20, Iss. 1, pp. 53-65
Open Access | Times Cited: 78
New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma
Michele Dal Bo, Elena De Mattia, Lorena Baboçi, et al.
Drug Resistance Updates (2020) Vol. 51, pp. 100702-100702
Open Access | Times Cited: 77
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives
Piera Federico, Angelica Petrillo, Pasqualina Giordano, et al.
Cancers (2020) Vol. 12, Iss. 10, pp. 3025-3025
Open Access | Times Cited: 71
Delivery of human natural killer cell-derived exosomes for liver cancer therapy: an in vivo study in subcutaneous and orthotopic animal models
Ho Yong Kim, Hyun-Ki Min, Hyeong‐Woo Song, et al.
Drug Delivery (2022) Vol. 29, Iss. 1, pp. 2897-2911
Open Access | Times Cited: 50
Page 1 - Next Page

Scroll to top